Cytokinetics, Incorporated · NASDAQ:CYTK
Callos Andrew sold 15,000 Cytokinetics, Incorporated shares (Form 4)
Traded Jun 1, 2026 · Filed Jun 1, 2026
On Jun 1, 2026, Callos Andrew (EVP, Chief Commercial Officer) sold 15,000 Cytokinetics, Incorporated shares at US$74.08 for US$1.11M under a trading plan, leaving 58,555 shares. Filed Jun 1, 2026 (Form 4).
- Sold
- 15,000 shares
- Price
- US$74.08
- Value
- US$1.11M
- Holding after
- 58,555 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- EVP, Chief Commercial Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | Option exercise | 15,000 | US$23.26 | 73,555 | Direct |
| Jun 1, 2026 | Common Stock | Sale | 15,000 | US$74.08 | 58,555 | Direct |
Source
Related
- Cytokinetics, Incorporated
- Callos Andrew
- Cytokinetics, Incorporated shareholders
- Form 4 · Callos Andrew · Aug 31, 2026
- Form 4 · Callos Andrew · Jul 30, 2026
- Form 4 · Callos Andrew · Jul 2, 2026
- Form 4 · Callos Andrew · May 5, 2026
- Form 4 · Callos Andrew · May 4, 2026
- Form 4 · Blum Robert I · Oct 13, 2026
- Form 4 · Malik Fady Ibraham · Oct 6, 2026
- Form 4 · Blum Robert I · Sep 28, 2026
- Form 4 · Malik Fady Ibraham · Sep 22, 2026
- Form 4 · Blum Robert I · Sep 15, 2026